PT  - JOURNAL ARTICLE
AU  - ,
AU  - Ganna, Andrea
TI  - Mapping the human genetic architecture of COVID-19: an update
AID  - 10.1101/2021.11.08.21265944
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.11.08.21265944
4099  - http://medrxiv.org/content/early/2022/02/09/2021.11.08.21265944.short
4100  - http://medrxiv.org/content/early/2022/02/09/2021.11.08.21265944.full
AB  - The Coronavirus Disease 2019 (COVID-19) pandemic continues to pose a major public health threat especially in countries with low vaccination rates. To better understand the biological underpinnings of SARS-CoV-2 infection and COVID-19 severity we formed the COVID19 Host Genetics Initiative. Here we present GWAS meta-analysis of up to 125,584 cases and over 2.5 million controls across 60 studies from 25 countries, adding 11 new genome-wide significant loci compared to those previously identified. Genes in novel loci include SFTPD, MUC5B and ACE2, reveal compelling insights regarding disease susceptibility and severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPlease refer to Supplementary Table 1 for information regarding individual studies involved in the COVID-19 Host Genetics InitiativeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Please refer to Supplementary Table 1 for information regarding individual studies involved in the COVID-19 Host Genetics InitiativeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://www.covid19hg.org https://www.covid19hg.org